DC-CIK as a widely applicable cancer immunotherapy-Reference-Cited by-同舟云学术

DC-CIK as a widely applicable cancer immunotherapy

Published:2020-02-13 Issue:6 Volume:20 Page:601-607
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Wang Shuo¹,Wang Xiaoli¹,Zhou Xinna¹,Lyerly Herbert Kim²,Morse Michael A.²³,Ren Jun¹²

Affiliation:

1. Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China

2. Department of Surgery, Duke University Medical Center, Durham, NC U.S.A

3. Department of Medicine, Duke University Medical Center, Durham, NC U.S.A

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2020.1728250

Reference47 articles.

1. Current Perspectives in Cancer Immunotherapy

2. Immuno-Oncology: Emerging Targets and Combination Therapies

3. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance

4. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors

5. Real‐world outcomes of sipuleucel‐T treatment in PROCEED, a prospective registry of men with metastatic castration‐resistant prostate cancer

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dysfunction of dendritic cells in tumor microenvironment and immunotherapy;Cancer Communications;2024-07-25

2. Efficacy of Chemoimmunotherapy versus Chemotherapy for Gastric Cancer: A Meta-Analysis of Survival Outcomes;Current Medicinal Chemistry;2024-06

3. Dendritic cell-derived exosome (DEX) therapy for digestive system cancers: Recent advances and future prospect;Pathology - Research and Practice;2024-05

4. Enhanced cellular therapy: revolutionizing adoptive cellular therapy;Experimental Hematology & Oncology;2024-04-25

5. Characterization of tumoricidal activities mediated by a novel immune cell regimen composing interferon-producing killer dendritic cells and tumor-specific cytotoxic T lymphocytes;BMC Cancer;2024-03-28